Latest News and Press Releases
Want to stay updated on the latest news?
-
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
-
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
-
Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a...
-
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
-
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
-
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
IN8bio Expands INB-100 Phase 1 Clinical Trial with addition of The Ohio State University as New Site
-
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
-
IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
-
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
-
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival